Literature DB >> 15991091

Contemporary management of thyroid cancer.

D Russell Blankenship1, Edward Chin, David J Terris.   

Abstract

Thyroid cancer is a relatively common and frequently curable malignant neoplasm, accounting for nearly 2% of all new cancers diagnosed annually in the United States. The diagnostic and management options have evolved considerably in the past decade, and a current understanding of these trends in the standard of care have assumed an important consideration in the practices of head and neck surgeons and endocrinologists alike. We sought to review the epidemiology and pathology of the several types of thyroid cancer and to present our evidence-based management algorithm. Every effort was made to offer alternative treatment strategies and supporting data where available. In addition to reviewing well-established approaches to diagnosis and management, emphasis is placed on newer techniques, including minimally invasive thyroidectomy, molecular detection of disease propensity, and the use of recombinant thyrotropin prior to radioiodine ablation.

Entities:  

Mesh:

Year:  2005        PMID: 15991091     DOI: 10.1016/j.amjoto.2005.01.019

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  11 in total

1.  (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.

Authors:  Kuan-Yin Ko; Chia-Hung Kao; Cheng-Li Lin; Wen-Sheng Huang; Ruoh-Fang Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-22       Impact factor: 9.236

2.  [Dysphagia and cervical space-occupying lesion].

Authors:  S Hölz; T Verse
Journal:  HNO       Date:  2007-10       Impact factor: 1.284

3.  Long-term survival in a patient with brain metastases of papillary thyroid carcinoma.

Authors:  Daniela Guelho; Cristina Ribeiro; Miguel Melo; Francisco Carrilho
Journal:  BMJ Case Rep       Date:  2016-03-09

4.  In vivo molecular targeted radiotherapy.

Authors:  Ac Perkins
Journal:  Biomed Imaging Interv J       Date:  2005-10-01

5.  Does radioiodine therapy in patients with differentiated thyroid cancer increase the frequency of another malignant neoplasm?

Authors:  Renata Midori Hirosawa; Monica Marivo; Juliana de Moura Leite Luengo; Jose Vicente Tagliarini; Emanuel Cellice Castilho; Mariangela de Alencar Marques; Yoshio Kiy; Marilia Martins Silveira Marone; Liciana Vaz de Arruda Silveira; Glaucia Maria Ferreira da Silva Mazeto
Journal:  ISRN Oncol       Date:  2011-08-14

6.  Long-Term Oncological Outcome Comparison between Intermediate- and High-Dose Radioactive Iodine Ablation in Patients with Differentiated Thyroid Carcinoma: A Propensity Score Matching Study.

Authors:  Kwangsoon Kim; Ja Seong Bae; Jeong Soo Kim
Journal:  Int J Endocrinol       Date:  2021-02-24       Impact factor: 3.257

7.  Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.

Authors:  Patricia J McLaughlin; Ian S Zagon; Sunny S Park; Andrea Conway; Renee N Donahue; David Goldenberg
Journal:  BMC Cancer       Date:  2009-10-18       Impact factor: 4.430

8.  Brain metastasis from papillary thyroid carcinomas.

Authors:  Kyoji Tsuda; Hideo Tsurushima; Shingo Takano; Koji Tsuboi; Akira Matsumura
Journal:  Mol Clin Oncol       Date:  2013-06-26

9.  Metastatic cerebellar tumor of papillary thyroid carcinoma mimicking cerebellar hemangioblastoma.

Authors:  Makoto Ideguchi; Takafumi Nishizaki; Norio Ikeda; Shigeki Nakano; Tomomi Okamura; Natsumi Fujii; Tokuhiro Kimura; Eiji Ikeda
Journal:  Springerplus       Date:  2016-06-29

10.  Pregnancy Outcome After I-131 Therapy for Patients With Thyroid Cancer: A Nationwide Population-Based Cohort Study.

Authors:  Kuan-Yin Ko; Ruoh-Fang Yen; Cheng-Li Lin; Mei-Fang Cheng; Wen-Sheng Huang; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.